Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-2.58% $8.68
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 611.95 mill |
EPS: | -2.44 |
P/E: | -3.56 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 70.50 mill |
Avg Daily Volume: | 2.23 mill |
RATING 2024-04-19 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.56 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.61x |
Company: PE -3.56 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.19 (-74.82%) $-6.49 |
Date: 2024-04-19 |
Expected Trading Range (DAY) |
---|
$ 7.77 - 9.65 ( +/- 10.76%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Greenway Schond L. | Sell | 5 560 | Common Shares |
2024-03-25 | Karlin Dan | Sell | 6 578 | Common Shares |
2024-03-25 | Barrow Robert | Sell | 16 519 | Common Shares |
2024-02-27 | Wernli Miri Halperin | Buy | 125 000 | Stock Option (Right to Buy) |
2024-02-27 | Greenway Schond L. | Buy | 150 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
90.12 |
Last 96 transactions |
Buy: 11 612 599 | Sell: 348 471 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $8.68 (-2.58% ) |
Volume | 1.516 mill |
Avg. Vol. | 2.23 mill |
% of Avg. Vol | 67.92 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.38 | N/A | Active |
---|
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.